

Fernando Bril

List of Publications by Citations

Source: <https://exaly.com/author-pdf/272844/fernando-bril-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

72
papers

3,513
citations

29
h-index

59
g-index

79
ext. papers

4,628
ext. citations

5.9
avg, IF

5.87
L-index

| # | Paper | IF | Citations |
|----|--|------|-----------|
| 72 | Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. <i>Annals of Internal Medicine</i> , 2016 , 165, 305-15 | 8 | 494 |
| 71 | High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 2231-8 | 5.6 | 304 |
| 70 | Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2014 , 60, 167-74 | 13.4 | 184 |
| 69 | Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. <i>Diabetes Care</i> , 2017 , 40, 419-430 | 14.6 | 172 |
| 68 | Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies. <i>Trends in Endocrinology and Metabolism</i> , 2017 , 28, 250-260 | 8.8 | 155 |
| 67 | Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2017 , 65, 1132-1144 | 11.2 | 134 |
| 66 | Nonalcoholic fatty liver disease: current issues and novel treatment approaches. <i>Drugs</i> , 2013 , 73, 1-14 | 12.1 | 123 |
| 65 | The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2015 , 61, 153-60 | 11.2 | 116 |
| 64 | Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2019 , 70, 711-724 | 11.2 | 112 |
| 63 | Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial. <i>Diabetes Care</i> , 2019 , 42, 1481-1488 | 14.6 | 105 |
| 62 | Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients. <i>Liver International</i> , 2015 , 35, 2139-46 | 7.9 | 104 |
| 61 | Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 558-566.e2 | 6.9 | 103 |
| 60 | Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 644-52 | 5.6 | 95 |
| 59 | Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis. <i>Hepatology</i> , 2014 , 59, 2178-87 | 11.2 | 89 |
| 58 | Relationship of vitamin D with insulin resistance and disease severity in non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2015 , 62, 405-11 | 13.4 | 85 |
| 57 | Nonalcoholic Fatty Liver Disease: The New Complication of Type 2 Diabetes Mellitus. <i>Endocrinology and Metabolism Clinics of North America</i> , 2016 , 45, 765-781 | 5.5 | 79 |
| 56 | MON-199 Targeting Pheochromocytoma/Paraganglioma with Polyamine Inhibitors. <i>Journal of the Endocrine Society</i> , 2020 , 4, | 0.4 | 78 |

| | | | |
|----|---|------|----|
| 55 | MON-644 Prevalence of Non-Alcoholic Fatty Liver Disease and Liver Fibrosis in Patients with Type 2 Diabetes Mellitus. <i>Journal of the Endocrine Society</i> , 2020 , 4, | 0.4 | 78 |
| 54 | Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2016 , 39, 632-8 | 14.6 | 76 |
| 53 | Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 812-821 | 6.7 | 65 |
| 52 | Cross-talk between branched-chain amino acids and hepatic mitochondria is compromised in nonalcoholic fatty liver disease. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2015 , 309, E311-9 | 6 | 63 |
| 51 | Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis. <i>Hepatology</i> , 2011 , 54, 837-45 | 11.2 | 63 |
| 50 | Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2020 , 43, 290-297 | 14.6 | 61 |
| 49 | Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?. <i>Journal of Hepatology</i> , 2021 , 75, 222-224 | 13.4 | 52 |
| 48 | Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 2950-2961 | 5.6 | 44 |
| 47 | Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening. <i>Diabetes Care</i> , 2021 , 44, 399-406 | 14.6 | 39 |
| 46 | Pioglitazone improves hepatic mitochondrial function in a mouse model of nonalcoholic steatohepatitis. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2018 , 315, E163-E173 | 6 | 34 |
| 45 | Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus. <i>Journal of Investigative Medicine</i> , 2019 , 67, 303-311 | 2.9 | 34 |
| 44 | Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 3327-3336 | 5.6 | 33 |
| 43 | Use of a metabolomic approach to non-invasively diagnose non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 1702-1709 | 6.7 | 24 |
| 42 | Antimicrobial agents-associated with QT interval prolongation. <i>Current Drug Safety</i> , 2010 , 5, 85-92 | 1.4 | 23 |
| 41 | Clinical and Histologic Characterization of Nonalcoholic Steatohepatitis in African American Patients. <i>Diabetes Care</i> , 2018 , 41, 187-192 | 14.6 | 23 |
| 40 | Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis. <i>Journal of Hepatology</i> , 2020 , 72, 401-410 | 13.4 | 21 |
| 39 | Use of Plasma Fragments of Propeptides of Type III, V, and VI Procollagen for the Detection of Liver Fibrosis in Type 2 Diabetes. <i>Diabetes Care</i> , 2019 , 42, 1348-1351 | 14.6 | 19 |
| 38 | Effect of pioglitazone on bone mineral density in patients with nonalcoholic steatohepatitis: A 36-month clinical trial. <i>Journal of Diabetes</i> , 2019 , 11, 223-231 | 3.8 | 16 |

| | | | |
|----|--|------|----|
| 37 | Role of Insulin Resistance and Diabetes in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease. <i>Current Hepatology Reports</i> , 2014 , 13, 159-170 | 1 | 16 |
| 36 | Plasma thyroid hormone concentration is associated with hepatic triglyceride content in patients with type 2 diabetes. <i>Journal of Investigative Medicine</i> , 2016 , 64, 63-8 | 2.9 | 16 |
| 35 | The challenge of managing dyslipidemia in patients with nonalcoholic fatty liver disease. <i>Clinical Lipidology</i> , 2012 , 7, 471-481 | | 15 |
| 34 | Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis. <i>Journal of Endocrinology</i> , 2019 , 241, 293-305 | 4.7 | 15 |
| 33 | A Genetic Score Associates With Pioglitazone Response in Patients With Non-alcoholic Steatohepatitis. <i>Frontiers in Pharmacology</i> , 2018 , 9, 752 | 5.6 | 14 |
| 32 | Adverse drug reactions as a reason for admission to an internal medicine ward in Argentina. <i>International Journal of Risk and Safety in Medicine</i> , 2013 , 25, 185-92 | 1.6 | 14 |
| 31 | Concentration-dependent response to pioglitazone in nonalcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 56-61 | 6.1 | 13 |
| 30 | High Prevalence of Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 100, | 5.6 | 13 |
| 29 | PPAR- δ -Induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH. <i>Liver International</i> , 2021 , 41, 2659-2670 | 7.9 | 13 |
| 28 | A Systematic Approach to Assess the Burden of Drug Interactions in Adult Kidney Transplant Patients. <i>Current Drug Safety</i> , 2016 , 11, 156-63 | 1.4 | 12 |
| 27 | A validated liquid chromatography tandem mass spectrometry method for simultaneous determination of pioglitazone, hydroxypioglitazone, and ketopioglitazone in human plasma and its application to a clinical study. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014 , 969, 219-23 | 3.2 | 10 |
| 26 | Autoimmunity after Coronavirus Disease 2019 (COVID-19) Vaccine: A Case of Acquired Hemophilia A. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 1674-1676 | 7 | 10 |
| 25 | Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: One or even several swallows do not make a summer. <i>Journal of Hepatology</i> , 2021 , 75, 1256-1257 | 13.4 | 7 |
| 24 | Liver fat accumulation as a barometer of insulin responsiveness again points to adipose tissue as the culprit. <i>Hepatology</i> , 2017 , 66, 296-297 | 11.2 | 5 |
| 23 | Relationship between non-alcoholic fatty liver disease during pregnancy and abnormal glucose metabolism during and after pregnancy. <i>Journal of Investigative Medicine</i> , 2020 , 68, 743-747 | 2.9 | 5 |
| 22 | Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis. <i>Annals of Internal Medicine</i> , 2017 , 166, 230 | 8 | 4 |
| 21 | Emerging Circulating Biomarkers for The Diagnosis and Assessment of Treatment Responses in Patients with Hepatic Fat Accumulation, Nash and Liver Fibrosis 2019 , 423-448 | | 4 |
| 20 | Targeting pheochromocytoma/paraganglioma with polyamine inhibitors. <i>Metabolism: Clinical and Experimental</i> , 2020 , 110, 154297 | 12.7 | 3 |

| | | | |
|----|--|------|---|
| 19 | Basic Concepts in Insulin Resistance and Diabetes Treatment 2018 , 19-35 | | 3 |
| 18 | Nonalcoholic Fatty Liver Disease (NAFLD) for Primary Care Providers: Beyond the Liver. <i>Current Hypertension Reviews</i> , 2021 , 17, 94-111 | 2.3 | 3 |
| 17 | Re: "Association Between Primary Hypothyroidism and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis" by Mantovani et al. (Thyroid 2018;28:1270-1284). <i>Thyroid</i> , 2019 , 29, 452 | 6.2 | 3 |
| 16 | 223-OR: Pioglitazone Discontinuation in Patients with Nonalcoholic Steatohepatitis (NASH) Is Associated with Disease Recurrence. <i>Diabetes</i> , 2019 , 68, 223-OR | 0.9 | 2 |
| 15 | Severity of non-alcoholic steatohepatitis is not linked to testosterone concentration in patients with type 2 diabetes. <i>PLoS ONE</i> , 2021 , 16, e0251449 | 3.7 | 2 |
| 14 | Response to Comment on Bril et al. Clinical and Histologic Characterization of Nonalcoholic Steatohepatitis in African American Patients. <i>Diabetes Care</i> 2018;41:187-192. <i>Diabetes Care</i> , 2018 , 41, e137-e138 | 14.6 | 2 |
| 13 | Treatment of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) 2015 , 292-305 | | 1 |
| 12 | Response to do ultrasonographic semiquantitative indices predict histological changes in NASH irrespective of steatosis extent?. <i>Liver International</i> , 2015 , 35, 2341-2 | 7.9 | 1 |
| 11 | Role of Vitamin E for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients with T2DM: A Randomized, Controlled Trial. <i>Diabetes</i> , 2018 , 67, 1223-P | 0.9 | 1 |
| 10 | 1461-P: Liver Fibrosis Is Common in Patients with Type 2 Diabetes Mellitus (T2DM) and Nonalcoholic Fatty Liver Disease (NAFLD). <i>Diabetes</i> , 2020 , 69, 1461-P | 0.9 | 1 |
| 9 | Intact Fasting Insulin Identifies Nonalcoholic Fatty Liver Disease in Patients Without Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e4360-e4371 | 5.6 | 1 |
| 8 | Central Nervous System Depressants and Risk of Hospitalization due to Community-Acquired Pneumonia in very Old Patients. <i>Current Drug Safety</i> , 2020 , 15, 131-136 | 1.4 | 0 |
| 7 | What the New Definition of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Left Behind: Genetically Acquired Fatty Liver Disease (GAFLD). <i>EBioMedicine</i> , 2021 , 72, 103584 | 8.8 | 0 |
| 6 | Reply to: "Comment on "Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?"". <i>Journal of Hepatology</i> , 2021 , 75, 996-997 | 13.4 | 0 |
| 5 | Letter to the Editor: "Hepatic Insulin Extraction in NAFLD Is Related to Insulin Resistance Rather Than Liver Fat Content". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 5249-5250 | 5.6 | |
| 4 | Drug Development for Diabetes Mellitus: Beyond Hemoglobin A1c 2019 , 405-421 | | |
| 3 | Use of Plasma Metabolomics and Lipidomics for the Diagnosis of Nonalcoholic Fatty Liver Disease in Type 2 Diabetes. <i>Diabetes</i> , 2018 , 67, 1847-P | 0.9 | |
| 2 | Exenatide Treatment Improves Mitochondrial Metabolism and Hepatic Insulin Sensitivity in Mice with Nonalcoholic Steatohepatitis (NASH). <i>Diabetes</i> , 2018 , 67, 1846-P | 0.9 | |

- 1 1463-P: Relationship between Hepatic and Adipose Tissue Insulin Resistance with Liver Fibrosis in Patients with Type 2 Diabetes Mellitus (T2DM) and Nonalcoholic Fatty Liver Disease (NAFLD). *Diabetes*, **2020**, 69, 1463-P 0.9